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Summary
Background Psoriasis, a chronic inflammatory skin disease, affects approximately 2%
of the population worldwide. Although the aetiology of psoriasis is poorly
understood, patients with disease of early onset (Type I, age of onset £ 40 years)
usually have a strong genetic component to the disease.
Objectives The purpose of this study was to investigate the role of the protein tyro-
sine phosphatase nonreceptor type 22 (PTPN22) gene region in susceptibility to
Type I psoriasis.
Patients and methods Thirteen single nucleotide polymorphisms (SNPs) mapping to
the PTPN22 region were genotyped in 647 patients with Type I psoriasis and 566
normal controls.
Results The rs2476601 (R620W) SNP, widely associated with other inflammatory
autoimmune diseases, showed no evidence of association with susceptibility to
Type I psoriasis. Two SNPs (rs1217414 and rs3789604) demonstrated significant
association with Type I psoriasis and were subsequently genotyped in a further
253 unrelated patients and 2024 normal controls. rs1217414 and rs3789604
were also significantly associated with Type I psoriasis in the combined datasets
(P = 0Æ003 and P = 0Æ0002, respectively); furthermore carriage of both risk
alleles was also significantly associated (P = 0Æ002).
Conclusions This study demonstrates evidence of association of two SNPs
(rs1217414 and rs3789604) in the PTPN22 region with Type I psoriasis, provid-
ing evidence for a role of this gene in Type I psoriasis that is not conferred by the
R620W variant previously associated with a number of inflammatory diseases.
Psoriasis is a chronic immune-mediated skin disease that
affects approximately 2% of the population worldwide.1 The
most common characteristics of the disease are red, well-
demarcated and heavily scaled plaques on the knees, elbows
and scalp but any skin surface can be affected. Most patients
(75%) of chronic plaque psoriasis first present before the age
of 40 years – known as early onset or Type I psoriasis. Late
onset or Type II psoriasis presents after the age of 40 years.2
Family studies have provided strong evidence that there is an
underlying genetic component to Type I psoriasis although
the precise mode of inheritance is poorly understood. Gen-
ome-wide scans on patients with psoriasis have identified a
number of key genomic regions linked to Type I disease.3–12
The best documented of these is psoriasis susceptibility region
1 (PSORS1) situated on chromosome 6p; here 35–50% of the
heritability of psoriasis is believed to be attributable to this
locus3 with a disease penetrance of 10–15%.13 The PSORS1
susceptibility region harbours the HLA-Cw6 allele which has a
strong association with Type I psoriasis; as many as 85% of
patients are HLA-Cw6 positive compared with 15% in Type II
patients.2 Aside from PSORS1, there is also a significant contri-
bution towards psoriasis susceptibility from non-HLA genes
and the identification of these loci are key to understanding
the full genetic component that underpins the pathogenesis of
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the disease. Potential candidate genes can be selected for in-
vestigation on the basis of their function or through overlap
with related conditions. In particular recent attention has
focused on the protein tyrosine phosphatase nonreceptor type
22 (PTPN22) gene.
The PTPN22 gene encodes the protein lymphoid tyrosine
phosphatase (Lyp) which has an N-terminal phosphatase
domain and a long, noncatalytic C-terminus with many pro-
line-rich motifs. The R620W polymorphism in PTPN22 is
associated with several immune-mediated diseases including
rheumatoid arthritis,14–16 Type I diabetes mellitus (initial dis-
ease associated),17 juvenile idiopathic arthritis,16 systemic
lupus erythematosus15 and autoimmune thyroid disease15 but
not others, including psoriasis15,16,18,19 and psoriatic arthri-
tis;16,20 however, speculation regarding the latter remains
because of a more recent publication that detected a positive
association with this marker.21 This polymorphism is located
in the N-terminal proline-rich motif, binding to the src
homology 3 binding domain Csk and results in a substitu-
tion of arginine with tryptophan. Studies have suggested that
the W620 variant has reduced binding to Csk, down-regulat-
ing the binding of Lyp with Csk.16 The mechanism(s)
underlying the reduced binding are not as yet fully under-
stood, with more recent publications stating that the poly-
morphism is in fact a gain of function regulator of T cells22
as opposed to a loss of function variant which was the initial
hypothesis.
Almost all studies of PTPN22 to date have focused on the
R620W variant including those failing to find association
with psoriasis. However, as activated T cells play a major
role in the pathogenesis of psoriasis, PTPN22 remains a
strong candidate gene for disease susceptibility.19 Therefore it
is possible that polymorphisms in PTPN22 other than R620W
may be important in psoriasis. A study of rheumatoid arthri-
tis patients screened multiple single nucleotide polymor-
phisms (SNPs) across the gene and identified associations
independent of R620W, illustrating the importance of sys-
tematic screening of this gene in autoimmune diseases.14 In
this study we describe an investigation of SNPs covering the
PTPN22 gene region in a case–control association study of
U.K. patients with psoriasis.
Materials and methods
The study was a case–control candidate gene investigation of
markers in the PTPN22 gene region carried out in a two-stage
design.
Stage 1
Recruitment of patients with Type I psoriasis for the initial
case cohort was coordinated through the Dermatology Centre,
Hope Hospital, The University of Manchester, Manchester,
U.K. All patients gave written informed consent and the study
was approved by the Salford and Trafford Local Research Eth-
ics Committee. In total 647 unrelated patients with Type I
psoriasis (53Æ8% male; 46Æ2% female; mean age of onset
20 years; 50Æ9% patients HLA-Cw6 positive) were compared
against 566 population-based controls of U.K. white ethnic
origin.
Stage 2
A second cohort of 253 unrelated patients with Type I psoria-
sis (64Æ8% male; 32Æ4 female; mean age of onset 21 years)
was provided by Guy’s Hospital, London, U.K. A further 2088
controls were available from the 1958 British Birth Cohort
study.23 These samples were used to evaluate further the SNPs
found to be associated (P < 0Æ05 in both trend and genotypic
association tests) in stage 1. The Oversight Committee for the
Biomedical Assessment of the British 1958 Birth Cohort Study
provided access to the DNA. Genotype data generated from
the 64 nonwhite individuals included in the cohort was not
included in the analysis, providing a total of 2024 controls
(50Æ1% male; 49Æ9% female).23
Single nucleotide polymorphism selection
Seven haplotype-tagging SNPs across PTPN22 were augmented
with three potentially functional SNPs, three SNPs with minor
allele frequencies of less than 5% to increase the power of
detecting association for rare SNPs and an additional SNP that
had shown the most significant association to rheumatoid
arthritis initially in an investigation by Carlton et al.14 who
produced this particular SNP panel (Fig. 1). Assays were
designed successfully for 13 of these markers.
Genotyping
Thirteen SNPs, including R620W, were genotyped in the
PTPN22 region using Sequenom MassArray technology
according to the manufacturer’s instructions using the iPLEX
chemistry.
Statistical analyses
The statistical software package STATA version 8.2 (StataCorp
Lp, College Station, TX, U.S.A.) was used to evaluate the dif-
ferences in allele and genotype frequencies of each SNP
between cases and controls and also to test the Hardy Wein-
berg equilibrium (HWE). Furthermore this software was used
to perform stepwise logistic regression on the allelic and
genotypic data of the combined dataset. Permutation testing of
the data was performed using the PLINK statistical package,24
assessing the empirical significance level of the associations
over 10 000 permutations.
Linkage disequilibrium
The genetic analysis software, HelixTree (Golden Helix
Incorporated, Bozeman, MT, U.S.A.) was used to calculate the
extent of linkage disequilibrium (LD) between the SNPs in the
 2008 The Authors
Journal Compilation  2008 British Association of Dermatologists • British Journal of Dermatology 2008 158, pp962–968
PTPN22 region and Type I psoriasis, Rh.Ll. Smith et al. 963
PTPN22 gene region. The parameters used for LD analysis are
D¢, which is a measure of the statistical significance of LD
between two SNPs, and r2 which is the square of the correl-
ation between two SNPs.
Results
Association testing: stage 1
In stage 1 of the study, two SNPs (rs1217414 and
rs3789604) demonstrated significant genotypic association
with Type I psoriasis (P £ 0Æ05 for both standard v2 and v2
test for trend, Table 1). No other SNPs, including R620W,
showed evidence of association with Type I psoriasis by these
tests (Table 1). The most significant difference in genotype
frequencies of patients with Type I psoriasis and controls from
stage 1 was observed for SNP rs1217414 (P = 0Æ0014), where
risk was conferred by carriage of two copies of the minor
allele (genotype TT) with an odds ratio (OR) = 2Æ39 (95% CI
1Æ43–4Æ11, P = 0Æ0005). However, the observed genotype
frequencies in the controls deviated significantly from the
expected number under the HWE for this SNP (P = 0Æ022).
Nonetheless, the associations remained significant when
comparing patient genotype frequencies with the expected
Fig 1. Map of the PTPN22 gene region and approximate location of genotyped SNPs.
Table 1 Genotype frequencies in cases and controls for Type I psoriasis in stage 1 of the study
SNP
Patients Controls
HWE in
controlsa
Genotypic
association
Trend
test
Genotype frequencies Genotype frequencies
1_1 (%) 1_2 (%) 2_2 (%) 1_1 (%) 1_2 (%) 2_2 (%)
exact
P-value v2
exact
P-value P-value
rs1217414 322 (50Æ79) 253 (39Æ91) 59 (9Æ31) 309 (55Æ38) 226 (40Æ50) 23 (4Æ12) 0Æ022 12Æ801 0Æ001 0Æ007
rs2488458 369 (57Æ75) 232 (36Æ31) 38 (5Æ95) 305 (55Æ56) 215 (39Æ16) 29 (5Æ28) 0Æ304 1Æ121 0Æ564 0Æ663
rs12760457 323 (50Æ71) 265 (41Æ60) 49 (7Æ69) 258 (46Æ57) 248 (44Æ77) 48 (8Æ66) 0Æ321 2Æ072 0Æ362 0Æ167
rs11102685 523 (81Æ97) 103 (16Æ14) 12 (1Æ88) 455 (81Æ40) 102 (18Æ25) 2 (0Æ36) 0Æ212 6Æ691 0Æ031 0Æ701
rs12730735 320 (50Æ79) 262 (41Æ59) 48 (7Æ62) 245 (47Æ39) 223 (43Æ13) 49 (9Æ48) 0Æ918 1Æ989 0Æ368 0Æ166
rs2476601 408 (80Æ79) 93 (18Æ42) 4 (0Æ79) 325 (82Æ70) 64 (16Æ28) 4 (1Æ02) 0Æ552 0Æ799 0Æ687 0Æ549
rs1310182 169 (34Æ00) 246 (49Æ50) 82 (16Æ5) 101 (28Æ77) 175 (49Æ86) 75 (21Æ37) 1Æ000 4Æ406 0Æ111 0Æ038
ss38346943b 487 (96Æ44) 18 (3Æ56) 0 (0Æ00) – – – – – – –
rs1217388 373 (57Æ92) 231 (35Æ87) 40 (6Æ21) 302 (54Æ32) 223 (40Æ11) 31 (5Æ58) 0Æ266 2Æ309 0Æ312 0Æ399
ss383469842 623 (96Æ89) 20 (3Æ11) 0 (0Æ00) 535 (97Æ45) 14 (2Æ55) 0 (0Æ00) 1Æ000 0Æ336 0Æ604 0Æ563
rs1217413 395 (62Æ30) 210 (33Æ12) 29 (4Æ57) 340 (62Æ85) 178 (32Æ90) 23 (4Æ25) 1Æ000 0Æ087 0Æ972 0Æ797
rs3811021 427 (67Æ14) 192 (30Æ19) 17 (2Æ67) 358 (64Æ74) 178 (32Æ19) 17 (3Æ07) 0Æ412 0Æ805 0Æ662 0Æ371
rs3789604 445 (73Æ68) 143 (23Æ68) 16 (2Æ65) 325 (64Æ61) 160 (31Æ81) 18 (3Æ58) 0Æ887 10Æ646 0Æ005 0Æ002
aHardy Weinberg equilibrium (HWE) statistic calculated in STATA 8.2 from comparing genotype frequencies expected under HWE against
the observed genotype frequencies.
bGenotype failure in the controls.
SNP, single nucleotide polymorphism.
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HWE frequencies for controls. The genotype frequencies of
rs3789604 were also significantly different when comparing
patients with Type I psoriasis and controls in the initial analy-
sis (Table 1). This association was based on a dominant model
of inheritance for the major allele with OR = 1Æ43 (95% CI
1Æ13–1Æ80, P = 0Æ002) with the trend in frequencies also sig-
nificant (Table 1) corresponding to an increase in major allele
T frequency and TT genotype.
Stage 2 and combined analysis
Markers rs1217414 and rs3789604 were genotyped in add-
itional case and control samples (n = 253 and n = 2024,
respectively). Because of the small numbers of patients with
psoriasis in the second cohort with an approximate 10 : 1
ratio of controls to patients, this additional genotype data
was combined with data from stage 1. There was no in-
creased evidence of association of rs1217414 with Type I
psoriasis in the combined data sets although the difference
in genotype frequency did remain significant (P = 0Æ003,
Table 2) with risk again conferred by carriage of two copies
of the minor allele with an odds ratio (OR) of 1Æ55 (95%
CI 1Æ16–2Æ08, P = 0Æ003). Permutation testing of the data
showed that the best model remained significant over
10 000 permutations for this marker (Table 2). In the com-
bined data sets an increased evidence of association was
obtained for SNP rs3789604 by both the standard v2 and v2
test for trend (P = 0Æ0002 and 0Æ0001, respectively; Table 2).
Association for the dominant model showed an OR of 1Æ35
(95% CI 1Æ16–1Æ58, P = 0Æ002) for the major allele. Further-
more, the assortment of cases and controls concluded that
the association had not occurred by chance following permu-
tation testing (Table 2).
HLA-Cw6 stratiﬁcation
Stratification of patients for HLA-Cw6 status (51% of patients
were HLA-Cw6 positive) was performed only at stage 1 of the
analysis. Association for rs1217414 and rs3789604 was signi-
ficant although reduced in the HLA-Cw6 positive patients with
P-values of 0Æ024 and 0Æ030, respectively (Table 3), suggest-
ing that association of these markers with psoriasis was not
dependent on HLA-Cw6 status.
Linkage disequilibrium analysis
Analysis of the control cohort using the HelixTree software
produced pairwise LD across the PTPN22 region (Fig. 2).
Table 2 Genotype frequencies in cases and controls for Type I psoriasis in the combined study
SNP Genotype
Combined analysis
Patients
n (%) Controls n (%)
HWE in
controlsa P-value
Trend
test
Permutation
(best model)b
rs1217414 CC 435 (49Æ54) 1301 (54Æ14)
CT 360 (41Æ00) 951 (39Æ58) 0Æ2041 0Æ003 0Æ002 0Æ013
TT 83 (9Æ46) 151 (6Æ28)
rs3789604 TT 613 (73Æ41) 1621 (65Æ63)
TG 199 (23Æ83) 765 (30Æ97) 0Æ6457 <0Æ001 <0Æ001 <0Æ001
GG 23 (2Æ76) 84 (3Æ40)
aHardy Weinberg equilibrium (HWE) statistic calculated in STATA 8.2 from comparing genotype frequencies expected under HWE against
the observed genotype frequencies.
bCorrected empirical P-value calculated for 10 000 permutations using PLINK software.
SNP, single nucleotide polymorphism.
Table 3 Genotype frequencies of PTPN22
region single nucleotide polymorphisms
(SNPs) in HLA-Cw6 positive cases and
controls
SNP Genotype
Stage 1
Patients
n (%)
Controls
n (%)
HWE in
controlsa P-value
Trend
test
rs1217414 CC 176 (51Æ9) 309 (55Æ4)
CT 134 (39Æ5) 226 (40Æ5) 0Æ0215 0Æ024 0Æ058
TT 29 (8Æ6) 23 (4Æ1)
rs3789604 TT 240 (73Æ4) 325 (64Æ6)
TG 79 (24Æ2) 160 (31Æ8) 0Æ8869 0Æ030 0Æ010
GG 8 (2Æ4) 18 (3Æ6)
aHardy Weinberg equilibrium (HWE) statistic calculated in STATA 8.2 from comparing
genotype frequencies expected under HWE against the observed genotype frequencies.
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D¢ and r2 were measured as parameters for LD structure. LD
was detected across the gene with D¢ > 0Æ95 for all SNPs
excluding ss38346943 and ss383469842. However, the r2
value showed that there were only five combinations of SNPs
strongly correlated (r2 > 0Æ8, Fig. 2). SNPs rs1217414 and
rs3789604, the two associated SNPs, demonstrated high D¢
(0Æ88) but low r2 (0Æ06) with each other. A comparison
between case and control LD plots showed no major differ-
ences in LD structure between the subgroups.
Stepwise logistic regression
Stepwise logistic regression was conducted on both associated
SNPs. The TT genotype of rs3789604 was the only significant
variable in the regression model regardless of SNP order;
OR = 1Æ39 (95% CI 1Æ15–1Æ68; P = 0Æ001).
Carriage of both associated risk alleles (TT) was associated
with a significantly increased risk of psoriasis; OR = 1Æ16
(95% CI: 1Æ02–1Æ33; P = 0Æ002). Interestingly, carrying nei-
ther risk allele (CG) was found to have a protective effect;
OR = 0Æ79 (95% CI: 0Æ67–0Æ93; P = 0Æ0003).
Discussion
The PTPN22 R620W polymorphism was not associated with
Type I psoriasis; this replicated the findings of previous
case–control studies.15,16,18,19 However, the investigation did
detect an association between psoriasis and two other
markers, namely rs1217414 and rs3789604, located in
intron 1 of PTPN22 and exon 1 of the round spermatid
basic protein 1 (RSBN1) gene downstream of PTPN22,
respectively. SNP rs3789604 showed the strongest associa-
tion with the disease in the combined analysis (P = 0Æ0002
and 0Æ0001 for v2 and the v2 trend test, respectively),
which remained significant after permutation testing.
Although the evidence for the association of rs1217414 was
not increased in the larger sample size, this remained sig-
nificant even after permutation testing. LD analysis demon-
strated that although D¢ LD was high between the alleles,
LD correlation (r2) between rs1217414 and rs3789604 was
low. SNP rs1217414 was excluded from stepwise logistic
regression with rs3789604, indicating that there is no add-
itional significant association with Type I psoriasis with this
marker conditional on SNP rs3789604. A closer examination
of these two markers revealed that 96% of individuals
homozygous for the minor allele (TT) for SNP rs1217414
were also homozygous for the major allele (TT) for
rs3789604 leading to the masking of rs1217414 by
rs3789604 (but not reversed) in the effect on the disease.
Carriage of both associated risk alleles (T allele for both
rs1217414 and rs3789604) revealed a significantly increased
risk of disease while carriage of the opposing alleles (C for
rs1217414 and G for rs3789604) demonstrated an even
greater protective effect against development of Type I
psoriasis.
The results of this study are supported by the findings of
a German study.18 In that study SNP rs2476601 was tested
initially in an exploratory case–control study of 375 indepen-
dent patients who were then combined with an additional
418 patients; there was no association with the R620W
polymorphism (P = 0Æ22 and P = 0Æ19, respectively). How-
ever, the same study revealed psoriasis susceptibility in or
near PTPN22 from haplotype analysis of four LD blocks
across the region on 1p13Æ2.18 The common haplotype in
three of the four LD blocks was found to be associated with
psoriasis with only two remaining significant following
Bonferroni correction (P = 0Æ02).18 Interestingly, the LD
blocks containing these associated haplotypes spanned the
region containing both the PTPN22 and RSBN1 genes; there-
fore the possibility remains that the associations detected in
this study could be due to LD with other SNPs across the
region. Furthermore, the rs3789604 marker has also been
associated with rheumatoid arthritis independently of the
well-characterized association with R620W.14 Interaction
studies between the PTPN22 risk haplotypes identified by
Huffmeier et al.18 and HLA-Cw6 returned negative estimates
for both associated haplotypes thereby excluding a direct
interaction between HLA-Cw6 and the causative allele within
PTPN22 for susceptibility to psoriasis. The current study
provides further evidence of lack of interaction between
PTPN22 and HLA-Cw6.
SNP rs3789604 is located in a predicted transcription factor
binding site in the 5¢ end and exonic region (exon 1) of the
Fig 2. Pairwise linkage disequilibrium pattern across the PTPN22
region. The genetic analysis software, HelixTree (Golden Helix
Incorporated) was used to calculate the extent of LD between both
the SNPs in the PTPN22 region. The parameters used for LD analysis
are D¢, which is a measure of the statistical significance of LD
between two SNPs reflecting historical recombination; and r2, which
is the square of the correlation between two SNPs thus measuring
the correlation between alleles at two loci. The extent of LD between
any two SNPs in this figure corresponds to the colour scale shown
where no LD (D¢ = 0 ⁄ r2 = 0) is white and complete LD
(D¢ = 1 ⁄ r2 = 1) is red.
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RSBN1 gene. This marker is 1496 base pairs downstream of
PTPN22 where the polymorphism results in either a synony-
mous mutation or putative transcription binding site.14 The
rs3789604 polymorphism lies within a predicted transcription
factor binding site for Pax-5, Pax-4, Nrf-1 and c-Myb.14 The
minor allele G is believed to alter the binding activity for
Pax-4 and Pax-5, which could regulate PTPN22 expression.14
Indeed, there is evidence of regulatory regions lying in adja-
cent genes, best described in the case of the sonic hedgehog
gene (SHH) where a mutation residing approximately 1 Mb
away from the gene called sasquatch (SSQ, now C6orf26) inter-
rupts a long-range cis-acting regulator that disrupts SHH
regulation and is thought to be responsible for preaxial
polydactyly disease (a common limb malformation) in
humans.25
The PAX genes are a family of transcription factors which
are of primary importance during organogenesis. Further-
more PAX5 encodes the B-cell specific activator protein
required for B lymphoid lineage.14 In the absence of PAX5,
pro-B cells have the potential to differentiate into functional
macrophages, osteoclasts, dendritic cells, granulocytes or nat-
ural killer cells depending on the cytokines inducing them,26
with a more recent publication determining that PAX5 func-
tions to determine B- vs. T-cell developmental fate.27 There-
fore it is conceivable that the rs3789604 polymorphism
determines or initiates T-cell activation at the site of plaques
of psoriasis. The SNP rs1217414 found to be associated
with Type I psoriasis in this study has not been identified
as associated with antibody-associated autoimmune diseases
and its exact function is therefore unknown. Located in
intron 1 of PTPN22 gene, it may have an effect on gene
transcription.
This study confirms that the R620W polymorphism is
not associated with Type I psoriasis thereby replicating
existing studies. Evidence of association of two SNPs in the
PTPN22 gene region with Type I psoriasis susceptibility may
suggest that altered levels in PTPN22 transcription may influ-
ence T-cell function and thereby influence susceptibility to
psoriasis.
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